



NATIONAL HEMOPHILIA FOUNDATION
for all bleeding disorders

MASAC Document #270
(Replaces Document #239)

**MASAC RECOMMENDATIONS ON SCREENING FOR DEVELOPMENT OF
HEPATOCELLULAR CANCER IN PATIENTS WITH HEPATITIS B AND C**

The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) on March 11, 2022, and adopted by the NHF Board of Directors on April 27, 2022.

Statement of Problem

Patients with viral hepatitis due to hepatitis B (HBV) and C (HCV) infection have been shown to have a significantly increased risk of end-stage liver disease, hepatocellular cancer (HCC), and death due to these two complications of infection. The incidence of hepatocellular cancer (HCC) is rising in many countries, including the United States. Cirrhosis due to hepatitis B (HBV) and hepatitis C (HCV) infection is a major driving force behind the increased incidence in the US. Non-alcoholic fatty liver disease (NAFLD) and its more severe form (non-alcoholic steatohepatitis, NASH) are also rising in incidence with NASH-induced cirrhosis becoming the most common cause of cirrhosis in the United States. All causes of cirrhosis lead to an increased risk of developing hepatocellular cancer (HCC).

Surveillance for HCC involves determining who is at risk for the development of HCC and deciding how to screen, how frequently to screen, and what the process should be to follow up on abnormal results.

Definition of the At Risk Population

The incidence of HCC in a particular population of patients is used to determine if screening is appropriate for that population. Current guidelines published by the American Association for the Study of Liver Disease (AASLD) and the American Gastroenterology Association (AGA) (Loomba et al, Ref. 3) are based on a decades-old tenet of cost effectiveness being achieved if an intervention can be done at a cost of about \$50,000 per year of life gained. There are published decision analysis/cost effectiveness models for HCC surveillance in chronic HBV/HCV infection and NASH. The risk of HCC is highest in patients who have cirrhosis, with an incidence of between 2-8% per year. Patients who are infected with HBV/HCV who do not have cirrhosis, or patients with NASH who do not have cirrhosis also have a higher risk of developing HCC so that screening may be indicated.

Patients who have Been Successfully Treated for their Chronic Hepatitis C Infection

Patients with cirrhosis from HCV infection who are successfully treated and clear the HCV virus are likely to have a reduced risk of developing HCC; however, data quantifying this reduced risk are not clear. It is likely that continued surveillance will become cost-ineffective

with time as the liver fibrosis improves and the risk of HCC diminishes. The current guidelines of the AASLD suggest that treated patients with cirrhosis should continue to undergo surveillance for HCC every 4-8 months until there is evidence that their cirrhosis and advanced fibrosis has resolved. The timeline for this improvement in fibrosis is unknown.

Patients who are Co-infected with HCV and HIV

Patients with HCV and HIV (HCV-HIV) co-infection are likely to have advanced liver disease. When these patients develop cirrhosis, they are at increased risk of HCC and at higher risk for more aggressive HCC. Therefore, these co-infected patients should undergo HCC surveillance. The criteria for screening are the same as for mono-infected patients.

Whom to Screen for HCC:

Based on guidelines from AASLD and the AGA (references below) these patients should be screened for HCC:

1. All patients with cirrhosis, regardless of the cause of their liver disease
2. Patients with NASH and stage 3 fibrosis (Metavir scale)
3. Patients with hepatitis B who meet certain age, gender and ethnicity characteristics:

AASLD Guidelines 2018

Population Group	Threshold Incidence for Efficacy of Surveillance (>0.25 LYG; % per year)	Incidence of HCC
Surveillance benefit		
Asian male hepatitis B carriers over age 40	0.2	0.4%-0.6% per year
Asian female hepatitis B carriers over age 50	0.2	0.3%-0.6% per year
Hepatitis B carrier with family history of HCC	0.2	Incidence higher than without family history
African and/or North American blacks with hepatitis B	0.2	HCC occurs at a younger age
Hepatitis B carriers with cirrhosis	0.2-1.5	3%-8% per year
Hepatitis C cirrhosis	1.5	3%-5% per year
Stage 4 PBC	1.5	3%-5% per year
Genetic hemochromatosis and cirrhosis	1.5	Unknown, but probably >1.5% per year
Alpha-1 antitrypsin deficiency and cirrhosis	1.5	Unknown, but probably >1.5% per year
Other cirrhosis	1.5	Unknown
Surveillance benefit uncertain		
Hepatitis B carriers younger than 40 (males) or 50 (females)	0.2	<0.2% per year
Hepatitis C and stage 3 fibrosis	1.5	<1.5% per year
NAFLD without cirrhosis	1.5	<1.5% per year

Abbreviation: LYG, life-years gained.

Marrero JA, Hepatology 2018; 68 (2): 723-750.

How to Screen for HCC

The most widely used radiological test for surveillance for HCC is an ultrasound. Ultrasound has been reported to have a sensitivity of greater than 90% when used as a screening test. Screening should be done using a high-quality ultrasound, specifically an ultrasound that is technically adequate based on overall radiologist impression of quality based on anatomic coverage (at least 2/3 of the liver visualized), visual clarity of the liver parenchyma (including heterogeneity and nodularity), depth of penetration, and other exam limitations such as obstruction from ribs, lungs, or bowel gas (Simmons et al, Ref. 4). In multivariable analysis in the latter study, inadequate

ultrasound quality was directly associated with male gender, increasing BMI, in-patient status, alcohol-related cirrhosis, and NASH-related cirrhosis.

The use of a CT scan as a screening tool for HCC has been studied; however, its performance characteristics are not known. The theoretical disadvantage of contrast use and high levels of radiation involved in a 4-phase CT scan have limited its use as a screening test for HCC. Strategies for alternating testing modalities (e.g. ultrasound alternating with CT scan or MRI) have no basis.

How to Follow-up Abnormal Screening Results

Patients with a high risk for HCC who enter a surveillance system need to be notified of an abnormal result. An abnormal result is a nodule not seen on a prior study but now noted to be present, regardless of the size of the nodule. An enlarging mass or nodule is always considered abnormal and should lead to further characterization. Most liver centers use an MRI or 4-phase CT to follow-up on an abnormal ultrasound. Individual centers may prefer one modality over the other.

Recommendations

1. Patients with hemophilia and hepatitis C who have documented cirrhosis should be screened for the development of hepatocellular cancer (HCC).
2. Patients with hemophilia who have hepatitis B infection and are not cirrhotic should be screened for the development of hepatocellular cancer (HCC) in specific cases based on age, gender, and ethnicity.
3. Patients with hemophilia who have NASH and advanced fibrosis (F3 on the Metavir fibrosis scale) but are not cirrhotic should be screened for the development of hepatocellular cancer (HCC).
4. Screening for HCC should be done using a high-quality ultrasound. A high-quality ultrasound is an ultrasound that is technically adequate based on overall radiologist impression of quality based on anatomic coverage (at least 2/3 of the liver visualized), visual clarity of the liver parenchyma (including heterogeneity and nodularity), depth of penetration, and other exam limitations such as obstruction from ribs, lungs, or bowel gas (Simmons et al, Ref. 4). In multivariable analysis in the latter study, inadequate ultrasound quality was directly associated with male gender, increasing BMI, in-patient status, alcohol-related cirrhosis and NASH-related cirrhosis.
5. Screening for HCC should be done at 4 to 8-month intervals. There is no need to change the frequency of the screening examinations for patients with a higher risk of HCC.
6. Patients with cirrhosis who have been treated and have cleared the hepatitis C virus should also continue to be screened to determine the amount of fibrosis with elastography and/or specialized blood tests annually until their liver fibrosis has improved to the point that they are no longer cirrhotic. This improvement in fibrosis is anticipated but does not always happen. Improvement in fibrosis may take years to reach the point where the risk of HCC is minimal and HCC screening is no longer warranted.

References

1. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management

- ofhepatocellular carcinoma: an update. *Hepatology*. 2011 Mar; 53(3): 1020-2.
2. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD; HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. *Gastroenterology*. 2009 Jan; 136(1): 138-48.
 3. Loomba R, Lim J, Patton H, El-Serag H. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. *Gastroenterology*. 2020; 158(6): 1822-1830.
 4. Simmons O, Fetzer DT, Yokoo T, Marrero JA, Uopp A, Kono Y, Parikh ND, Browning T, Singal AG. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. *Aliment Pharmacol Ther* 2017 Jan; 45(1):169-177.
 5. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2018 Mar; 68(2): 723-750.

This material is provided for your general information only. NHF does not give medical advice or engage in the practice of medicine. NHF under no circumstances recommends particular treatment for specific individuals and in all cases recommends that you consult your physician or local treatment center before pursuing any course of treatment.

Copyright 2022 National Hemophilia Foundation. To facilitate the dissemination of these medical recommendations, reproduction of any material in this publication in whole or in part will be permitted provided: 1) a specific reference to the MASAC recommendation number and title is included and 2) the reproduction is not intended for use in connection with the marketing, sale or promotion of any product or service. NHF reserves the right to make the final determination of compliance with this policy. For questions or to obtain a copy of the most recent recommendations, please contact the NHF Senior Vice President for Programs and Medical Information at handi@hemophilia.org or visit the NHF website at www.hemophilia.org.